These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30472330)

  • 41. Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.
    Huang JF; Zeng DZ; Duan GJ; Shi Y; Deng GH; Xia H; Xu HQ; Zhao N; Fu WL; Huang Q
    PLoS One; 2015; 10(12):e0145698. PubMed ID: 26701781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
    Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
    Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS testing in clinical laboratory: optimizing targeted therapy.
    Miravalle L; Lefferts JA; Al-Haddad M; Tsongalis GJ; Cheng L
    Cancer Genomics Proteomics; 2012; 9(5):337-41. PubMed ID: 22990113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
    Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
    Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma].
    Wang Q; Zhong M; Lü YL; Yuan J; Wei LX
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):603-6. PubMed ID: 23157828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform.
    Guarnaccia M; Iemmolo R; San Biagio F; Alessi E; Cavallaro S
    Sensors (Basel); 2018 Jan; 18(1):. PubMed ID: 29304017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
    Luo Y; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification.
    Pratt ED; Cowan RW; Manning SL; Qiao E; Cameron H; Schradle K; Simeone DM; Zhen DB
    Anal Chem; 2019 Jun; 91(12):7516-7523. PubMed ID: 31072097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highly specific detection of KRAS single nucleotide polymorphism by asymmetric PCR/SERS assay.
    Lyu N; Rajendran VK; Li J; Engel A; Molloy MP; Wang Y
    Analyst; 2021 Sep; 146(18):5714-5721. PubMed ID: 34515700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
    Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
    Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hot-Spot-Specific Probe (HSSP) for Rapid and Accurate Detection of KRAS Mutations in Colorectal Cancer.
    Lee HJ; Koo B; Jang YO; Liu H; Dao TNT; Lim SB; Shin Y
    Biosensors (Basel); 2022 Aug; 12(8):. PubMed ID: 36004993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [KRAS gene mutation in colorectal cancer].
    Roa I; Sánchez T; Majlis A; Schalper K
    Rev Med Chil; 2013 Sep; 141(9):1166-72. PubMed ID: 24522420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
    Taly V; Pekin D; Benhaim L; Kotsopoulos SK; Le Corre D; Li X; Atochin I; Link DR; Griffiths AD; Pallier K; Blons H; Bouché O; Landi B; Hutchison JB; Laurent-Puig P
    Clin Chem; 2013 Dec; 59(12):1722-31. PubMed ID: 23938455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection.
    Ou CY; Vu T; Grunwald JT; Toledano M; Zimak J; Toosky M; Shen B; Zell JA; Gratton E; Abram TJ; Zhao W
    Lab Chip; 2019 Mar; 19(6):993-1005. PubMed ID: 30735225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
    Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
    Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
    Awidi M; Ababneh N; Shomaf M; Al Fararjeh F; Owaidi L; AlKhatib M; Al Tarawneh B; Awidi A
    PLoS One; 2019; 14(12):e0226473. PubMed ID: 31881025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.